SAB Biotherapeutics, Inc. (SABS) stock

SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30

$2.96−0.12 (-3.90%)

Close on Nov 13, 2026Market cap $269.32MP/E –Yield –

SAB Biotherapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

SAB Biotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in SAB Biotherapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5.67 reverse split on Mar 29, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SABS.

Revenue growth-100.0% · median 7.1%

Advertisement
300 × 250

See a number that looks wrong?